• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

墨西哥和阿根廷六个月随访期间不同加强疫苗组合对 SARS-CoV-2 的有效性。

Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.

机构信息

Research Department, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico.

Vicerrectoría de Ciencias de la Salud, Escuela de Medicina, Universidad de Monterrey, San Pedro Garza García, Mexico.

出版信息

Front Immunol. 2024 May 14;15:1403784. doi: 10.3389/fimmu.2024.1403784. eCollection 2024.

DOI:10.3389/fimmu.2024.1403784
PMID:38807602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11130401/
Abstract

INTRODUCTION

Given the limited number of patients in Latin America who have received a booster dose against the COVID-19, it remains crucial to comprehend the effectiveness of different vaccine combinations as boosters in real-world scenarios. This study aimed to assess the real-life efficacy of seven different vaccine schemes against COVID-19, including BNT162b2, ChAdOx1-S, Gam-COVID-Vac, and CoronaVac as primary schemes with either BNT162b2 or ChAdOx1-S as booster vaccines.

METHODS

In this multicentric longitudinal observational study, participants from Mexico and Argentina were followed for infection and SARS-CoV-2 Spike 1-2 IgG antibodies during their primary vaccination course and for 185 days after the booster dose.

RESULTS

A total of 491 patients were included, and the booster dose led to an overall increase in the humoral response for all groups. Patients who received BNT162b2 exhibited the highest antibody levels after the third dose, while those with primary Gam-COVID-Vac maintained a higher level of antibodies after six months. Infection both before vaccination and after the booster dose, and Gam-COVIDVac + BNT162b2 combination correlated with higher antibody titers.

DISCUSSION

The sole predictor of infection in the six-month follow-up was a prior COVID-19 infection before the vaccination scheme, which decreased the risk of infection, and all booster vaccine combinations conveyed the same amount of protection.

摘要

简介

鉴于拉丁美洲接受 COVID-19 加强针的患者人数有限，了解不同疫苗组合在现实场景中作为加强针的有效性仍然至关重要。本研究旨在评估七种不同疫苗方案（包括 BNT162b2、ChAdOx1-S、Gam-COVID-Vac 和 CoronaVac 作为基础疫苗，以及 BNT162b2 或 ChAdOx1-S 作为加强疫苗）对 COVID-19 的真实世界疗效。

方法

在这项多中心纵向观察性研究中，来自墨西哥和阿根廷的参与者在其基础疫苗接种期间和加强针接种后 185 天内，对感染和 SARS-CoV-2 Spike 1-2 IgG 抗体进行了随访。

结果

共纳入 491 名患者，加强针接种后所有组的体液反应均总体增加。接受 BNT162b2 加强针的患者在第三针后抗体水平最高，而原发性 Gam-COVID-Vac 的患者在六个月后仍保持较高的抗体水平。接种前和加强针接种后的感染以及 Gam-COVID-Vac+BNT162b2 组合与更高的抗体滴度相关。

讨论

在六个月的随访中，唯一的感染预测因素是疫苗接种方案前的 COVID-19 感染，这降低了感染风险，所有加强疫苗组合都具有相同的保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/d91df6d28107/fimmu-15-1403784-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/21761cbed2c6/fimmu-15-1403784-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/d1c4612fea52/fimmu-15-1403784-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/d91df6d28107/fimmu-15-1403784-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/21761cbed2c6/fimmu-15-1403784-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/d1c4612fea52/fimmu-15-1403784-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d56/11130401/d91df6d28107/fimmu-15-1403784-g003.jpg

相似文献

1
Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.墨西哥和阿根廷六个月随访期间不同加强疫苗组合对 SARS-CoV-2 的有效性。
Front Immunol. 2024 May 14;15:1403784. doi: 10.3389/fimmu.2024.1403784. eCollection 2024.
2
Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.墨西哥海军人员中两剂BNT162b2 mRNA新冠疫苗加一剂ChAdOx1-S加强针的免疫原性
Viruses. 2024 Apr 1;16(4):551. doi: 10.3390/v16040551.
3
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.在科兴或牛津阿斯利康新冠疫苗初免系列接种后，四种针对新冠病毒变异株的新冠疫苗加强针的免疫原性和反应原性。
Asian Pac J Allergy Immunol. 2024 Sep;42(3):276-289. doi: 10.12932/AP-160123-1533.
4
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.BNT162b2 或 mRNA-1273 异源加强接种后 SARS-CoV-2 IgA、IgG、中和和总抗体反应的随访和比较评估。
Influenza Other Respir Viruses. 2024 May;18(5):e13290. doi: 10.1111/irv.13290.
5
Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.新冠病毒加强疫苗接种后医护人员队列的后续严重急性呼吸综合征冠状病毒2血清学研究
BMC Infect Dis. 2024 Apr 24;24(1):436. doi: 10.1186/s12879-024-09338-5.
6
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.科兴新冠疫苗、辉瑞疫苗、腺病毒载体新冠疫苗加强免疫后针对新冠病毒刺突受体结合域 IgG 抗体应答的比较：一项前瞻性、纵向基于人群的研究。
Lancet Microbe. 2022 Apr;3(4):e274-e283. doi: 10.1016/S2666-5247(21)00305-0. Epub 2022 Feb 9.
7
Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.健康成年人适应 COVID-19 疫苗接种方案后对 SARS-CoV-2 的体液免疫反应：IMCOVAS 随机临床试验。
Vaccine. 2024 Nov 14;42(25):126117. doi: 10.1016/j.vaccine.2024.07.018. Epub 2024 Jul 16.
8
Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.BNT162b2 疫苗第三剂对医护人员定量 SARS-CoV-2 刺突 1-2 IgG 抗体滴度的影响。
PLoS One. 2022 Mar 2;17(3):e0263942. doi: 10.1371/journal.pone.0263942. eCollection 2022.
9
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中，第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
10
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.两种 COVID-19 基础疫苗系列免疫原性的持续差异，由加强 mRNA 疫苗接种和突破性感染调节。
Vaccine. 2024 Jul 25;42(19):3953-3960. doi: 10.1016/j.vaccine.2024.05.003. Epub 2024 May 9.

引用本文的文献

1
Vaccination Strategies: Mixing Paths Versus Matching Tracks.疫苗接种策略：混合路径与匹配轨迹
Vaccines (Basel). 2025 Mar 13;13(3):308. doi: 10.3390/vaccines13030308.

本文引用的文献

1
Antibody Response to COVID-19 Vaccines in Healthcare Workers: Which One is More Successful? Homologous or Heterologous?医护人员对新冠疫苗的抗体反应：哪种更有效？同源接种还是异源接种？
Sisli Etfal Hastan Tip Bul. 2023 Jun 20;57(2):216-223. doi: 10.14744/SEMB.2023.48264. eCollection 2023.
2
Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.同源/异源加强 COVID-19 疫苗接种方案对三国一般人群和临床亚组中重症的有效性。
Vaccine. 2023 Nov 13;41(47):7007-7018. doi: 10.1016/j.vaccine.2023.10.011. Epub 2023 Oct 17.
3
Comparative Safety and Effectiveness of Heterologous CoronaVac-ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study.
真实世界中异源科兴疫苗-牛津阿斯利康疫苗与同源科兴疫苗接种的比较安全性和有效性：一项回顾性队列研究
Vaccines (Basel). 2023 Sep 5;11(9):1458. doi: 10.3390/vaccines11091458.
4
A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran.一项前瞻性队列研究方案：在伊朗，先前接种过两剂国药或卫星 V 疫苗的人群中，监测和随访接种牛津阿斯利康 COVID-19 异源加强针后的不良事件。
BMC Public Health. 2023 Jul 24;23(1):1415. doi: 10.1186/s12889-023-16265-8.
5
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.在科兴或牛津阿斯利康新冠疫苗初免系列接种后，四种针对新冠病毒变异株的新冠疫苗加强针的免疫原性和反应原性。
Asian Pac J Allergy Immunol. 2024 Sep;42(3):276-289. doi: 10.12932/AP-160123-1533.
6
Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy.中国优化疫情防控“动态清零”政策后奥密克戎变异株突破性感染轻症患者的临床特征
Vaccines (Basel). 2023 May 10;11(5):968. doi: 10.3390/vaccines11050968.
7
Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico.六种不同的新冠病毒疫苗在巴西和墨西哥六个月随访及五次新冠疫情浪潮期间的有效性
Vaccines (Basel). 2023 Apr 14;11(4):842. doi: 10.3390/vaccines11040842.
8
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
9
Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis.异源免疫接种方案对 COVID-19 疫苗的免疫原性和反应原性：系统评价和网络荟萃分析。
Chin Med J (Engl). 2023 Jan 5;136(1):24-33. doi: 10.1097/CM9.0000000000002567.
10
Waning of humoral immunity depending on the types of COVID-19 vaccine.体液免疫的减弱取决于新冠疫苗的类型。
Infect Dis (Lond). 2023 Mar;55(3):216-220. doi: 10.1080/23744235.2023.2165707. Epub 2023 Jan 10.